Drugs /

mogamulizumab

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
mogamulizumab

Clinical Trials

View Clinical Trials for mogamulizumab

Mogamulizumab has been investigated in 10 clinical trials, of which 8 are open and 2 are closed. Of the trials investigating mogamulizumab, 3 are phase 1 (2 open), 4 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open).

EGFR A763_Y764insFQEA, EGFR Exon 19 Deletion, and EGFR Exon 19 Insertion are the most frequent biomarker inclusion criteria for mogamulizumab clinical trials.

Sezary syndrome, mycosis fungoides, and adult T-cell leukemia/lymphoma are the most common diseases being investigated in mogamulizumab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Mogamulizumab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Mogamulizumab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating mogamulizumab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
kw-0761
Drug Categories [2]:
Immunotherapies, Therapeutic antibodies
Drug Target(s) [2]:
CCR4

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.